Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Prostatic Neoplasms 3Brain Neoplasms 2Oligodendroglioma 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1Gliosarcoma 1Glioma 1Glioblastoma 1Castrate-resistant Metastatic Prostate Cancer 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 5Temozolomide 2Immunotherapy, Adoptive 2Aminolevulinic Acid 2thymoglobulin 1temsirolimus 1poly ICLC 1pembrolizumab 1pazopanib 1orludodstat 1keyhole-limpet hemocyanin 1gallium Ga 68 dotatate 1fludarabine phosphate 1fluciclovine F-18 1dexamethasone acetate 1dexamethasone 21-phosphate 1cixutumumab 1carbon-11 acetate 1cabazitaxel 1bicalutamide 1azeliragon 1auricularum 1atezolizumab 1abemaciclib 1Valproic Acid 1Trail Making Test 1Topotecan 1Thiotepa 1Tacrolimus 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Glioma × cabazitaxel × Clear all
NCT01740570 2018-01-19

Phase I/II Cabazitaxel for Recurrent Malignant Glioma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡